+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epinephrine Autoinjectors - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • September 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5028116
The global market for Epinephrine Autoinjectors was estimated at US$2.5 Billion in 2023 and is projected to reach US$3.6 Billion by 2030, growing at a CAGR of 4.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the The 0.15 gm Dosage Epinephrine Autoinjectors segment, which is expected to reach US$2.5 Billion by 2030 with a CAGR of 4.6%. The 0.30 gm Dosage Epinephrine Autoinjectors segment is also set to grow at 5.6% CAGR for the next 8-year period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $756.1 Million in 2023, and China, forecasted to grow at an impressive 4.5% CAGR to reach $634.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Epinephrine Autoinjectors Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Epinephrine Autoinjectors Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Epinephrine Autoinjectors Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as ALK-Abello A/S, Bausch + Lomb UK Ltd- Emerade, Teva Pharmaceutical Industries Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • ALK-Abello A/S
  • Bausch + Lomb UK Ltd- Emerade
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 and a Looming Global Recession
  • Epinephrine Autoinjectors - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Epinephrine Autoinjectors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Individuals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for 0.15 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for 0.30 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for 0.5 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 23: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 29: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: Canada 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
JAPAN
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Japan 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 35: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: Japan 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
CHINA
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: China Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: China 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 41: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: China Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: China 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
EUROPE
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: Europe 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
FRANCE
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: France Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: France 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 56: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: France Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: France 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
GERMANY
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: Germany 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 62: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Germany 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: Italy 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 68: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: Italy 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: UK Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: UK 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 74: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: UK Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: UK 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 77: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: Rest of Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: Rest of Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: Asia-Pacific Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 89: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of World Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of World Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ALK-Abello A/S
  • Bausch + Lomb UK Ltd- Emerade
  • Teva Pharmaceutical Industries Ltd.

Table Information